125I放射性粒子植入治疗恶性纤维组织细胞瘤术后肺转移瘤的短期效果观察

Short-term clinical efficacy of 125I radioactive seeds implantation in treating the postoperative lung metastases of malignant fibrous histiocytoma

目的探讨cT引导下经皮穿刺放射性125I粒子肿瘤内植入治疗恶性纤维组织细胞瘤（MFH）术后肺转移瘤的短期临床效果。方法选择MFH术后肺转移瘤患者8例，转移病灶28个，行cT引导下经皮穿刺肿瘤内放射性125I粒子植入，处方剂量80Gy，粒子活度0．7mCi（2．59×107Bq）。粒子植入术后6个月复查胸部CT，与粒子植入前比较肿瘤变化，按照国际标准判定疗效。结果接受粒子植入的瘤体平均照射剂量（172．9±39．9）Gy，D100（77．7±10．2）Gy，D90（97．2±6．8）Gy。有效率为82．1％（23／28），患者术后生存10．0～26．0个月，平均（14．64-3．5）个月，中位生存期13．0个月。结论放射性粒子对MFH肺部转移病灶短期局部效果明显。

Objective To investigate the short-term clinical efficacy of CT-guided percutaneous implantation of 125I radioactive seeds in treating the postoperative lung metastases of malignant fibrous histiocytoma（MFH） . Methods Eight patients with lung metastases after MFH surgery received CT-guided percutaneous implantation of 125I radioactive seeds. There are 28 metastasis lesions in total. Prescribed dose （PD） was 80 Gy and radioactivity was 0. 7 mCi （2. 59 ± 107 Bq）. Six months after implantation, chest CT-scan was performed and the changes were reviewed according to the international standards. Results Average dose received by tumor was （ 172. 9 ± 39. 9） Gy, D100 （77.7 ± 10. 2） Gy and D90 （97. 2 ± 6. 8 ） Gy. The overall response rate was 82. 1%. Patients＇ survival period was 10. 0 - 26.0 （ 14. 6 ±3.5 ） months with the median survival time of 13 months. Conclusion In the treatment of postoperative lung metastases of MFH,implantation of 125I radioactive seeds produces a good short-term clinical efficacy.